Italia markets closed

Dow Jones
39.872,99
+66,22(+0,17%)
Nasdaq
16.832,62
+37,75(+0,22%)
Nikkei 225
38.946,93
-122,75(-0,31%)
EUR/USD
1,0859
-0,0002(-0,02%)
Bitcoin EUR
64.130,29
-21,60(-0,03%)
CMC Crypto 200
1.508,63
+20,08(+1,35%)

NVCR Jan 2025 22.500 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

7,30

0,00

(0,00%)

In data: 11:33AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in